TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02396550

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Expectations
Description: Give positive expectation of the treatment efficacy to patients

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mobilization with movement
Description: Give neutral expectation of the treatment efficacy to patients

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mobilization with movement
Description: Give neutral expectation of the treatment efficacy to patients
Study: NCT02373605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling,Thrust Manipulation
Description: HVLA thrust manipulation to upper cervical and upper thoracic regions. Dry needling to cervicothoracic and craniofacial regions. Up to 8 treatment sessions over 4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise,Non-thrust Mobilization
Description: Non-thrust mobilization and exercise to upper cervical and upper thoracic regions. Up to 8 treatment sessions over 4 weeks.
Study: NCT01038401

Intervention type: PROCEDURE
Group type: OTHER
Intervention: GI endoscopy and GALT biopsies
Description: This project aims to characterize the residual replication of HIV-1 in subjects on HAART, particularly in the gut-associated lymphoid tissue (GALT)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: GI endoscopy and GALT biopsies
Description: This project aims to characterize the residual replication of HIV-1 in subjects on HAART, particularly in the gut-associated lymphoid tissue (GALT)
Study: NCT02293395

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor 90 mg twice daily orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor 90 mg twice daily orally.
Study: NCT00949715

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic or Vitatron Dual-Chamber Pacemaker
Description: A Medtronic or Vitatron market-approved dual-chamber implantable pulse generator (IPG) with atrial tachycardia/atrial fibrillation (AT/AF) trending ability

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic or Vitatron Dual-Chamber Pacemaker
Description: A Medtronic or Vitatron market-approved dual-chamber implantable pulse generator (IPG) with atrial tachycardia/atrial fibrillation (AT/AF) trending ability

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic SelectSecure 3830 Lead
Description: Medtronic market-approved SelectSecure Model 3830 bipolar pacing lead

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic SelectSecure 3830 Lead
Description: Medtronic market-approved SelectSecure Model 3830 bipolar pacing lead
Study: NCT03361891

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WalkMORE Group
Description: Hospitalized Internal Medicine patients will walk with trained volunteer coaches twice daily until hospital discharge
Study: NCT00224770

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MIS+Cathflo Activase (drug)
Description: MIS+Cathflo Activase (drug): The intervention is a comparison of the safety and preliminary effectiveness of investigational minimally invasive surgery to place a catheter into an intracerebral hemorrhage blood clot and subsequent administration in sequential tiers of 0.3 or 1.0mg of rt-PA, CathFlo® through the catheter once every eight hours for up to 72 hours, in addition to best medical care.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative stereotactic CT-Guided Endoscopic Surgery
Description: Mechanical intracerebral hemorrhage removal via an endoscope utilizing the same operative targeting arm as MISTIE arm. No rt-PA administered, and in addition to best medical care.
Study: NCT02366897

Intervention type: DEVICE
Group type: OTHER
Intervention: Manus Sensor Pen
Description: Manus Sensor Pen as made by Manus Neurodynamica Ltd
Study: NCT03808610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV
Study: NCT03729102

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood drawn after rabies vaccine booster vaccination
Description: All participants would be given one dose of rabies vaccine and monitor the immunological cells i.e., regulatory T cell, regulatory B cell, T follicular helper cells, cytokines i.e., IL-10, TGF-Beta, and Rabies neutralizing antibody titers, before and after the booster injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood drawn after rabies vaccine booster vaccination
Description: All participants would be given one dose of rabies vaccine and monitor the immunological cells i.e., regulatory T cell, regulatory B cell, T follicular helper cells, cytokines i.e., IL-10, TGF-Beta, and Rabies neutralizing antibody titers, before and after the booster injection
Study: NCT02950857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPEG
Description: (Pegylated erythropoeitin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPEG
Description: (Pegylated erythropoeitin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPEG
Description: (Pegylated erythropoeitin)
Study: NCT01862952

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: starting of anti-epileptic drug treatment
Study: NCT01038401

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: A sample of venous blood will also be collected
Description: These samples of blood will be use to characterize the residual viral populations on effective HAART in three compartments, plasma, monocytes, and GALT
Study: NCT03644901

Intervention type: PROCEDURE
Intervention: nonsurgical periodontal treatment
Description: patients will undergo nonsurgical periodontal treatment to reduce the relative attachment level and improve the probing depth. An initial session will be conducted to remove supra gingival plaque and calculus. another appointment is set to perform full moth scalling and root planing.

Intervention type: PROCEDURE
Intervention: nonsurgical periodontal treatment
Description: patients will undergo nonsurgical periodontal treatment to reduce the relative attachment level and improve the probing depth. An initial session will be conducted to remove supra gingival plaque and calculus. another appointment is set to perform full moth scalling and root planing.

Intervention type: PROCEDURE
Intervention: nonsurgical periodontal treatment
Description: patients will undergo nonsurgical periodontal treatment to reduce the relative attachment level and improve the probing depth. An initial session will be conducted to remove supra gingival plaque and calculus. another appointment is set to perform full moth scalling and root planing.

Intervention type: PROCEDURE
Intervention: nonsurgical periodontal treatment
Description: patients will undergo nonsurgical periodontal treatment to reduce the relative attachment level and improve the probing depth. An initial session will be conducted to remove supra gingival plaque and calculus. another appointment is set to perform full moth scalling and root planing.
Study: NCT03736343

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol
Description: Participants will complete two drinking sessions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol
Description: Participants will complete two drinking sessions.
Study: NCT00004935

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin™ (Her)
Description: Herceptin™ (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks; at time of progression add chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin™ (Her) + chemo
Description: Herceptin™ (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks, and chemotherapy
Study: NCT04344041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cholecalciferol 200,000 IU
Description: Patients receive a vitamin D supplementation of 400,000 IU in a single oral dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol 50,000 IU
Description: Patients receive a vitamin D supplementation of 50,000 IU in a single oral dose
Study: NCT03276637

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Whole exome sequencing
Description: Whole exome sequencing at 125x coverage (i.e., at least 125 sequencing reads covering each position within the exome region of interest) performed at the Laboratory of Molecular Medicine's Clinical Laboratory Improvement Amendments (CLIA) certified laboratory on 75 enrolled individuals
Study: NCT04425343

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: 16s RNA Metagenomics sequencing
Description: The subgingival plaque was collected using a sterile curette from the buccal aspect of maxillary molars and lingual aspect of mandibular incisors, in a vial containing 200µl of Buffer CL.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: 16s RNA Metagenomics sequencing
Description: The subgingival plaque was collected using a sterile curette from the buccal aspect of maxillary molars and lingual aspect of mandibular incisors, in a vial containing 200µl of Buffer CL.
Study: NCT02450721

Intervention type: OTHER
Intervention: Biomarkers serum level measurement
Description: Biomarker serum level measurement was performed with ELISA using following kits: Lp-PL-A2 ELISA- Cloud-CloneCorp. (USA); PAPP-A ELISA- IBL (Germany); Lp (a) ELISA Kit-AssayPro (USA ), ADMA ELISA Kit- ImmunDiagnostik ( Germany); hsCRP ELISA- Biomerica (Germany); according to the manufacturer's instructions . Absorbance of standards and samples was measured with a microplate reader Bio-Tek (USA) at a wavelength specified by the kit manufacturer . The calculation of the determined biomarkers concentration was performed using the software SOFTmaxPRO.

Intervention type: OTHER
Intervention: Biomarkers serum level measurement
Description: Biomarker serum level measurement was performed with ELISA using following kits: Lp-PL-A2 ELISA- Cloud-CloneCorp. (USA); PAPP-A ELISA- IBL (Germany); Lp (a) ELISA Kit-AssayPro (USA ), ADMA ELISA Kit- ImmunDiagnostik ( Germany); hsCRP ELISA- Biomerica (Germany); according to the manufacturer's instructions . Absorbance of standards and samples was measured with a microplate reader Bio-Tek (USA) at a wavelength specified by the kit manufacturer . The calculation of the determined biomarkers concentration was performed using the software SOFTmaxPRO.

Intervention type: OTHER
Intervention: Biomarkers serum level measurement
Description: Biomarker serum level measurement was performed with ELISA using following kits: Lp-PL-A2 ELISA- Cloud-CloneCorp. (USA); PAPP-A ELISA- IBL (Germany); Lp (a) ELISA Kit-AssayPro (USA ), ADMA ELISA Kit- ImmunDiagnostik ( Germany); hsCRP ELISA- Biomerica (Germany); according to the manufacturer's instructions . Absorbance of standards and samples was measured with a microplate reader Bio-Tek (USA) at a wavelength specified by the kit manufacturer . The calculation of the determined biomarkers concentration was performed using the software SOFTmaxPRO.
Study: NCT02088203

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose 1
Description: Russian Tarragon Nutrasorb 0.3 g

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose 1
Description: Russian Tarragon Nutrasorb 0.3 g

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose 1
Description: Russian Tarragon Nutrasorb 0.3 g

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose 1
Description: Russian Tarragon Nutrasorb 0.3 g
Study: NCT02272842

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin B12
Description: Vitamin B12 in a multivitamin paste.
Study: NCT02088203

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose 1
Description: Russian Tarragon Nutrasorb 0.3 g

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose 1
Description: Russian Tarragon Nutrasorb 0.3 g

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose 1
Description: Russian Tarragon Nutrasorb 0.3 g

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose 1
Description: Russian Tarragon Nutrasorb 0.3 g

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose 1
Description: Russian Tarragon Nutrasorb 0.3 g

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose 2
Description: Russian Tarragon Nutrasorb 1 g

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose 2
Description: Russian Tarragon Nutrasorb 1 g
Study: NCT02272842

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: Vitamin B12 in a multivitamin paste.
Study: NCT00798343

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Seasonal vaccine
Description: Non-adjuvanted seasonal influenza vaccine (total dose 45ug)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5 vaccine
Description: MF59-adjuvanted A/Vietnam/1194 H5N1 vaccine 7.5ug dose
Study: NCT02602132

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clamping
Description: To clamp before the removal of short-term indwelling urethral catheters
Study: NCT03551717

Intervention type: OTHER
Intervention: Optical Coherence Tomography angiography
Description: At the inclusion visit for all patients and at M3 only for 50 patients.

Intervention type: OTHER
Intervention: Optical Coherence Tomography angiography
Description: At the inclusion visit for all patients and at M3 only for 50 patients.
Study: NCT02088203

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose 6
Description: Russian Tarragon Nutrasorb 30 g
Study: NCT02722343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir intravaginal ring
Description: The participant will wear the intravaginal ring consecutively for 14 days and nights. Following study product use and at study visit 4, blood and genital tract samples will be taken (to include cervico-vaginal fluid and tissue)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Truvada
Description: The participant will take the tablet for 14 days. taking one tablet each morning. Following study product use and at study visit 4, blood and genital tract samples will be taken (to include cervico-vaginal fluid and tissue)
Study: NCT02183935

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Duodena-jejunal liner
Study: NCT03933384

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir alafenamide
Description: Tenofovir alafenamide 25mg/tab once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: Entecavir 0.5mg/tab once daily
Study: NCT02710305

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral hyoscine butyl bromide tablets plus lidocaine cream
Description: patients will take oral hyoscine butyl bromide 30 minutes before the procedure plus lidocaine anesthetic cream placed into their cervix immediately before the procedure
Study: NCT03551717

Intervention type: OTHER
Intervention: Fundus
Description: At the inclusion visit for all patients and at M3 only for 50 patients.

Intervention type: OTHER
Intervention: Fundus
Description: At the inclusion visit for all patients and at M3 only for 50 patients.
Study: NCT02710305

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oral placebo tablets plus placebo cream
Description: patients will take oral placebo 30 minutes before the procedure plus placebo cream placed into their cervix immediately before the procedure
Study: NCT00327184

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Haemophilus influenzae type b- and meningococcal serogroup C (vaccine)
Description: Two primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age.
Study: NCT03551717

Intervention type: OTHER
Intervention: cardiac ultrasound scan
Description: Only for 50 patients, 3 months after the initial cardiovascular event
Study: NCT04119076

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classroom-based physical activity

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Study: NCT00327184

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix Penta
Description: Two primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix hexa
Description: Two primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age
Study: NCT03514485

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yes We Can Children's Asthma Program
Description: The Yes We Can Children's Asthma Program intervention is a medical-social model based on a chronic care approach, including risk stratification, clinical care management, social care coordination by a community health worker, and primary care physician asthma champions. This intervention includes asthma education, trigger reduction visits and care coordination. There will be five clinic visits and four home visits over 12 months implemented by the primary care CHW who is integrated into the primary care practice.
Study: NCT00327184

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Neis-Vac-C
Description: Two primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age
Study: NCT04242446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Subjects will receive bimekizumab at pre-specified time-points.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Subjects will receive bimekizumab at pre-specified time-points.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Subjects will receive bimekizumab at pre-specified time-points.
Study: NCT04637581

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wraparound
Description: Wraparound is a 12-month family-driven intensive care coordination model.
Study: NCT02480374

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMNN-001
Study: NCT02655016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.
Study: NCT04459715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xevinapant (Debio 1143)
Description: Xevinapant (Debio 1143) administrated as oral solution from Day 1 to 14, every 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin administered as an IV infusion every 3 weeks (Q3W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin administered as an IV infusion every 3 weeks (Q3W).

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity Modulation Radiation Therapy (IMRT)
Description: 70 Gy given in 35 fractions over 7 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulation Radiation Therapy (IMRT)
Description: 70 Gy given in 35 fractions over 7 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matched placebo administrated as oral solution from Day 1 to 14, every 21-day cycle.
Study: NCT04310397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Spartalizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study: NCT02779764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: roxadustat
Description: Oral
Study: NCT03644485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus immediate-release formulation
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus immediate-release formulation
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus prolonged-release formulation
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus prolonged-release formulation
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction therapy
Description: All participants will receive induction therapy. The dosage and administration of induction immunotherapy will be a single kind of drug determined by the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction therapy
Description: All participants will receive induction therapy. The dosage and administration of induction immunotherapy will be a single kind of drug determined by the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolic acid drugs
Description: All participants will receive mycophenolic acid drugs in combination with corticosteroids. The dosage and administration of mycophenolic acid will be determined by the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolic acid drugs
Description: All participants will receive mycophenolic acid drugs in combination with corticosteroids. The dosage and administration of mycophenolic acid will be determined by the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: All participants will receive corticosteroids in combination with mycophenolic acid drugs. The dosage and administration of corticosteroids will be determined by the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: All participants will receive corticosteroids in combination with mycophenolic acid drugs. The dosage and administration of corticosteroids will be determined by the investigator.
Study: NCT03626363

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Management
Description: An eight week stress reduction course.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Management
Description: An eight week stress reduction course.